Topic: infectious respiratory diseases

AstraZeneca pulls PD-L1 combo test, RSV candidate

It’s the fourth-quarter clear out, and AstraZeneca has pulled the plug on a combo of its immuno-oncology candidate as well as axing a test of its biologic arm’s RSV drug as it sheds some more light on its tests in head and neck cancers.